Abstract
Thyrotropin (TSH)-secreting adenomas are rare and, as most adenomas are large, invasive and difficult to cure by surgery only, many require additional medical treatment. Many TSH-secreting adenomas cosecrete growth hormone (GH) and/or prolactin (PRL). We evaluated the relationship between pathology and the effect of dopamine agonist bromocriptine and somatostatin analogue octreotide in 20 operated patients with TSH-secreting adenomas. The four men and 16 women ranged in age from 23 to 62 years; three had clinically overt acromegaly; two manifested galactorrhea-amenorrhea. Endocrinologically, elevated serum GH, and/or IGF-1 were observed in six patients and elevated serum PRL was observed in eight. Immunohistochemically, 16 of the 20 adenomas were positive for GH and/or PRL (GH-positive, n=13; PRL-positive, n=9). Pituitary-specific transcription factor Pit-1 was demonstrated in the nuclei of all adenoma cells. Octreotide tests showed suppression of serum TSH (<50%) in ten of 14 patients. Preoperative octreotide treatment effectively reduced serum TSH and tumor size in two patients. Electron micrographs of octreotide-treated TSH-secreting adenomas showed shrinkage of the cytoplasm and diffuse distribution of secretory granules. Our study suggests that cosecretion of GH and/or PRL from TSH-secreting adenoma has no correlation with response of tumor cells to medical treatment.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00401-004-0863-x/MediaObjects/s00401-004-0863-xflb1.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00401-004-0863-x/MediaObjects/s00401-004-0863-xflb2.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00401-004-0863-x/MediaObjects/s00401-004-0863-xfhb3.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00401-004-0863-x/MediaObjects/s00401-004-0863-xfhb4.jpg)
Similar content being viewed by others
Reference
Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP (1993) Cell type specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. J. Clin Endocrinol Metab 77:1275–1280
Beckers A, Abs R, Mahler C, Vandalem JL, Pirens G, Hennen G, Stevenaert A (1991) Thyrotropin-secreting pituitary adenomas: report of seven cases. J Clin Endocrinol Metab 72:477–483
Beck-Peccoz P, Piscitelli G, Amr S, Ballabio M, Bassetti M, Giannattasio G, Spada A, Nissim M, Weintraub BD, Faglia G (1986) Endocrine, biochemical and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH) and alpha-subunit: evidence for secretion of TSH with increased bioactivity. J Clin Endocrinol Metab 62:704–711
Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610–638
Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J (1992) Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 75:540–546
Bevan JS, Burke CW, Esiri MM, Adams CB, Ballabio M, Nissim M, Faglia G (1989) Studies of two thyrotropin-secreting pituitary adenomas: evidence for dopamine deficiency. Clinical Endocrinol 31:59–70
Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD (1999) Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Cllin Endocrinol Metab 84:476-486
Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P (2001) Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotroin-secreting pituitary adenomas. J Clin Endocrinol Metab 86:2849–2853
Chanson P, Weingraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119:236–240
Comi R, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317:12–17
Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM (1992) Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Int Med 117:711–718
Ezzat S, Horvath E, Harris AG, Kovacs K (1994) Morphological effects of octreotide on growth hormone- producing pituitary adenomas. J Clin Endocrinol Metab 79:113–118
Ezzat S, Horvath E, Kovacs K, Smyth HS, Sriger W, Asa SL (1995) Basic fibroblast growth factor expression by two prolactin and thyrotropin producing pituitary adenomas. Endocrin Pathol 6:125–134
Frawley LS, Boockfor FR (1991) Mammosomatotropes: Presence and functions in normal and neoplastic pituitary tissue. End Rev 12:337–355
Gesundheit N, Petrick PA, Nissim M, Dahlberg PA, Doppman JL, Emerson CH, Braverman LE, Oldfield EH, Weintraub BD (1989) Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity: case reports and follow -up of nine patients. Ann Intern Med 11:827–35
Greenman Y, Melmed S (1995) Thyrotropin-secreting pituitary tumors. In: Melmed S, ed, The pituitary. Blackwell, Boston, pp 546–558
Hill SA, Walko JM, Wilson CB, Hunt WE (1982) Thyrotropin-producing pituitary adenomas. J Neurosurg 57:515–519
McCutcheon IE, Weintraub BD, Oldfield EH (1990) Surgical treatment of thyrotropin-secreting pituitary adenomas. J Neurosurg 73:674–683
Mindermann T, Wilson CB (1993) Thyrotropin-producing pituitary adenomas. J Neurosurg 79:521–527
Radian S, Coculescu M, Morris JF (2003) Somatotroph to thyrotroph cell transdifferentiation during experimental hypothyroidism—a light and elecron-microscopy study. J Cell Mol Med 7:297–306
Sanno N, Teramoto A, Matsuno A, Osamura RY (1994) Clinical and immunohistochemical studies on TSH-secreting pituitary adenoma : Its multihormonality and expression of Pit- 1. Mod Pathol 7:893–899
Sanno N, Teramoto A, Matsuno A, Osamura RY (1995) Studies on GH and PRL gene expression by Non-radioisotopic in situ hybridization in TSH-secreting pituitary adenomas. J Clin Endocrinol Metab 80:2518–2522
Sanno N, Teramoto A, Matsuno A, Osamura RY (1996) Expression of human Pit-1 product in the human pituitary and pituitary adenomas. Arch Pathol Lab Med 120:73–77
Sanno N, Teramoto A, Osamura RY (2000) Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg 93:194–200
Sanno N, Osamura RY, Teramoto A, Horvath E, Kovacs K (2003) Pathology of pituitary tumors. Neurosurg Clin N Am 14:25–39
Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 41:51–58
Valdes Socin H, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148:433–442
Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, Harris AG (1991) Shrinkage of primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201–995). Acta Endocrinol 124:487–491
Wood DF, Johnston JM, Johnston DG (1991) Dopamine, the dopamine D2 receptor and pituitary tumors. Clin Endocrinol 35:455–466
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teramoto, A., Sanno, N., Tahara, S. et al. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Acta Neuropathol 108, 147–153 (2004). https://doi.org/10.1007/s00401-004-0863-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-004-0863-x